{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:06:17Z","timestamp":1791407177053,"version":"4.3.3"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>INTRODUCTION<\/jats:title><jats:p>Consensus definitions of meaningful within\u2010patient change (MWPC) on the Clinical Dementia Rating\u2010Sum of Boxes (CDR\u2010SB) are needed. Existing estimates use clinician\u2010rated anchors in clinically diagnosed Alzheimer's disease (AD) populations. Incorporating the care partner perspective offers important insights, and evaluating biomarker\u2010confirmed cohorts aligns estimates with ongoing trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Anchor\u2010based analyses were conducted to evaluate MWPC on the CDR\u2010SB in early AD (Tauriel; NCT03289143) using Caregiver Global Impression of Change in memory or daily activities.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Across time points and anchors, mean CDR\u2010SB changes associated with the \u201csomewhat worse\u201d category ranged from 1.50 to 2.12 in early AD, 1.07 to 2.06 in mild cognitive impairment\u2010AD, and 1.79 to 2.25 in mild AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>DISCUSSION<\/jats:title><jats:p>The proposed ranges are appropriate to define meaningful progression on the CDR\u2010SB in similar cohorts and support the interpretation of treatment benefit through MWPC analyses. Thresholds should be calibrated to the context of use; lower\/higher thresholds may be applicable in studies of earlier\/later disease over shorter\/longer durations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Highlights<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Within\u2010patient CDR\u2010SB change thresholds are provided using caregiver\u2010rated anchors.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>1.5 to 2.5 points may be an appropriate range in early AD trials of similar durations.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Cumulative distribution function plots illustrate the benefit of a given treatment.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>When selecting thresholds, the target population and study design should be considered.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1002\/alz.14050","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T03:45:41Z","timestamp":1721187941000},"page":"5889-5900","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Care partner\u2010informed meaningful change thresholds for the Clinical Dementia Rating\u2010Sum of Boxes for trials of early Alzheimer's disease"],"prefix":"10.1002","volume":"20","author":[{"given":"Claire J.","family":"Lansdall","sequence":"first","affiliation":[{"name":"Product Development, Patient\u2010Centered Outcomes Research F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Teng","sequence":"additional","affiliation":[{"name":"Early Clinical Development Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Chague","sequence":"additional","affiliation":[{"name":"Product Development, Data Science F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Palanganda","sequence":"additional","affiliation":[{"name":"Product Development, Data Science Roche Products Ltd  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Delmar","sequence":"additional","affiliation":[{"name":"Product Development, Data Science F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Smith","sequence":"additional","affiliation":[{"name":"Product Development, Neuroscience Roche Products Ltd  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[{"name":"Chambers\u2010Grundy Center for Transformative Neuroscience University of Nevada  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDougall","sequence":"additional","affiliation":[{"name":"Product Development, Patient\u2010Centered Outcomes Research Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.12"},{"key":"e_1_2_10_3_1","unstructured":"US Food and Drug Administration (FDA).Collecting comprehensive and representative input. Accessed December 2023.https:\/\/www.fda.gov\/media\/139088\/download"},{"key":"e_1_2_10_4_1","unstructured":"US Food and Drug Administration (FDA).Patient\u2010focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision\u2010making. Accessed June 2024.https:\/\/www.fda.gov\/media\/166830\/download"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000089218"},{"key":"e_1_2_10_6_1","unstructured":"US Food and Drug Administration (FDA).Incorporating clinical outcome assessments into endpoints for regulatory decision\u2010making. Accessed October 2023.https:\/\/www.fda.gov\/media\/132505\/download"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479015622667"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173554"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.102"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12181"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.04.001"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.1375"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022\u20103956(75)90026\u20106"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.11.2412\u2010a"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1076\/jcen.20.3.310.823"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.8.1091"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2020.73"},{"key":"e_1_2_10_23_1","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_10_24_1","first-page":"28","article-title":"The Clinical Global Impressions Scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","journal-title":"Psychiatry"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.9"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0163278705275339"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1037\/\/0033\u20102909.112.1.155"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0895\u20104356(99)00071\u20102"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.101"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.4.2.159"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.14050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T21:05:20Z","timestamp":1759957520000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.14050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/alz.14050"],"URL":"https:\/\/doi.org\/10.1002\/alz.14050","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"2024-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}